BBIO - BridgeBio Pharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

BBIO is currently covered by 17 analysts with an average price target of $102.59. This is a potential upside of $24.41 (31.22%) from yesterday's end of day stock price of $78.18.

Our record on BridgeBio Pharma covers 29 analysts since 2008; 17 cover it today. Of the 272 price targets those analysts set on BBIO, 218 were reached (80%). The highest performance score on BridgeBio Pharma belongs to Anupam Rama of JPMorgan: 7.49, with 18 of 20 targets met in 210 days on average. The latest calls: Sean Laaman of Morgan Stanley raised the target to $91 from $88 with a Buy rating on 12 Nov 2026; Whitney Ijem of Canaccord raised the target to $108 from $106 with a Buy rating on 1 Nov 2026; Tyler Van Buren of TD Cowen cut the target to $100 from $110 with a Buy rating on 29 Oct 2026. Figures as of 18 Nov 2026.

BridgeBio Pharma's activity chart (see below) currently has 334 price targets and 299 ratings on display. The stock rating distribution of BBIO is 94.83% BUY and 5.17% HOLD.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 76.26% of the time, taking 230.96 days on average.

Highest price target for BBIO is $156, Lowest price target is $80, average price target is $102.59.

Most recent stock forecast was given by SEAN LAAMAN from MORGAN STANLEY on 12-Nov-2026. First documented stock forecast 21-Jul-2019.

Best performing analysts who are covering BBIO - BridgeBio Pharma:

Joshua Schimmer Tiago Fauth Cory Kasimov Eliana Merle Andrew Tsai

Currently out of the existing stock ratings of BBIO, 55 are a BUY (94.83%), 3 are a HOLD (5.17%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 05-Jan-2026

$91

$12.83 (16.41%)

$88

7 days ago
(12-Nov-2026)

0/7 (0%)

$12.83 (16.41%)

Buy Since 02-Jun-2026

$108

$29.83 (38.16%)

$106

18 days ago
(01-Nov-2026)

0/3 (0%)

$33 (44.00%)

Buy Since 21-Jul-2019

$100

$21.83 (27.93%)

$110

21 days ago
(29-Oct-2026)

5/9 (55.56%)

$25.05 (33.42%)

215

Hold Since 18-May-2026

$91

$12.83 (16.41%)

$93

1 months 1 days ago
(18-Oct-2026)

1/3 (33.33%)

$23.06 (33.94%)

51

Buy Since 03-Sep-2024

$120

$41.83 (53.51%)

$115

1 months 1 days ago
(18-Oct-2026)

11/15 (73.33%)

$52.06 (76.63%)

188

Show more analysts

Please expand the browser size to see the chart

What is BBIO (BridgeBio Pharma) average time for price targets to be met?

On average it took 231 days for the stock forecasts to be reached, with an average price target met ratio of 76.26%.

Which analyst most recently updated their price target on BBIO (BridgeBio Pharma)?

Sean Laaman

Which analyst has the most public recommendations on BBIO (BridgeBio Pharma)?

Sean Laaman works at MORGAN STANLEY and has 17 price targets and 10 ratings on BBIO

Which analyst is the currently most bullish on BBIO (BridgeBio Pharma)?

Eliana Merle with the highest potential upside of $77.83

Which analyst is the currently most reserved on BBIO (BridgeBio Pharma)?

Thomas Shrader with the lowest potential downside of -$46.17
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?